# Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

> **NCT01559077** · PHASE1 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- TTR-mediated Amyloidosis

## Interventions

- **DRUG:** ALN-TTR02
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT01559077
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01559077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01559077, "Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01559077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*